Newtyn Partners, LP and Newtyn TE Partners, LP, managed by Newtyn Management, LLC made a proposal to acquire remaining 93.48% stake in Sensei Biotherapeutics, Inc. (NasdaqGM:SNSE) for $25 million on October 25, 2023. Newtyn proposed to acquire remaining shares of Sensei Biotherapeutics, Inc. at a price equal to $1.00 per share in cash. Proposal is subject to receipt of required Board and stockholder approvals; receipt of any required governmental and third-party approvals (including under applicable antitrust laws and material contracts); satisfactory completion of due diligence; and the execution of a definitive agreement containing terms and conditions customary for a transaction of this type and size.

The transaction would not be subject to any financing contingency.